Printer Friendly

Eli Lilly R&D Center steps up fight against cancer.

NEW YORK--About 140 scientists have begun work at Eli Lilly & Co.'s new cancer research facility in New York. The complex is focused on speeding to market a new generation of potential breakthrough cancer medicines.

Occupying 90,000 square feet of office/laboratory space, Lilly is the anchor tenant at the Alexandria Center for Life Science-New York City, located along Manhattan's East Side medical corridor just north of Bellevue Hospital and adjacent to New York University's Langone Medical Center. The center now houses the research activities of ImClone Systems, a wholly owned subsidiary of Lilly (Lilly acquired ImClone in 2008) along with certain rights to already-marketed Erbitux and ImClone's pipeline of oncology biologics.

At the site, ImClone scientists will conduct preclinical discovery efforts involving potential new biotechnology medicines for patients with cancer.


"We are driven by our goal of improving outcomes for individual patients. Our strong biotechnology research capability working with several therapeutic areas is one of the key ways we are executing in this innovation strategy," says Jan Lundberg, executive vice president of science and technology and president of Lilly Research Laboratories.

"The ImClone research move to the Alexandria Center will provide state-of-the-art laboratory facilities and help us foster internal and external innovation and promote collaboration."

Lilly has two other biotechnology centers in the United States, one in San Diego and the other at its corporate headquarters in Indianapolis. Of these, the biotechnology center in New York is the only one specifically dedicated to discovering potential new cancer medicines.

The company has a long history in biotechnology research and development, beginning with the introduction of the first commercially produced biologic (insulin) in 1923. Sixty years later Lilly, in collaboration with a partner, ushered in the modern era of biotechnology by producing the first recombinant DNA-based biologic: human insulin.

"My colleagues and I are excited about being part of the Alexandria Center, where we will continue our discovery efforts for new breakthrough biotech treatments that have the potential to truly change cancer care for patients around the world," comments John Johnson, president of Lilly oncology and senior vice president at Lilly.

"We are using biomarkers and applying new tools and technologies to tailor our potential medicines during the earliest stages of development, including the preclinical work that our researchers are conducting at this new world-class facility."

COPYRIGHT 2010 Racher Press, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2010 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:RX RETAIL PHARMACY: Biotechnology; Eli Lilly and Co.; research and development
Publication:Chain Drug Review
Geographic Code:1USA
Date:Oct 25, 2010
Previous Article:Biotech will change nature of Rx practice.
Next Article:Rigel hits two research milestones.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters